DEVELOPMENT OF NEW SECOND GENERATION MOLECULES FOR CANCER IMMUNOTHERAPY (Q4191440): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed label, description and/or aliases in es, and other parts: Adding Spanish translations)
(‎Changed label, description and/or aliases in en, and other parts: Adding English translations)
label / enlabel / en
 
DEVELOPMENT OF NEW SECOND GENERATION MOLECULES FOR CANCER IMMUNOTHERAPY
Property / summary
 
LIMMUNOTERAPIA BASED ON IMMUNOLOGICAL CHECKPOINT INHIBITORS REPRESENTS THE EMERGING SECTOR OF CANCER THERAPY, WITH AN EXPONENTIAL GROWTH MARKET. IN PARTICULAR, MONOCLONAL ANTIBODIES (MABS) CAPABLE OF INHIBITING CTLA-4, PD-1 AND PD-L1, APPROVED FOR SEVERAL SOLID TUMOURS AND HODGKIN’S LYMPHOMA, ARE ABLE TO REACTIVATE A GENERALISED ANTI-CANCER IMMUNE RESPONSE, PROVIDING FOR THE FIRST TIME A THERAPEUTIC AARMA TO PATIENTS WITH ADVANCED TUMOURS WITH REDUCED LIFE PERSPECTIVE. DESPITE LENTUSIASMO FOR THE RESULTS ACHIEVED SO FAR, MABS EFFICACY FOR IMMUNOTHERAPY APPROVED TO DATE IS LIMITED TO A PORTION OF TUMOURS (10-30 % OF CASES), AND IS FREQUENTLY ASSOCIATED WITH ALLÂINSORGERE OF AUTOIMMUNE ADVERSE EVENTS. THEREFORE, A LARGE PROPORTION OF TREATED PATIENTS (APPROXIMATELY 15 %) SHOULD DISCONTINUE DRUG TREATMENT DUE TO UNCURABLE ADVERSE REACTIONS. FINALLY, MANY PATIENTS ARE NOT ELIGIBLE FOR THESE TREATMENTS AT (English)
Property / summary: LIMMUNOTERAPIA BASED ON IMMUNOLOGICAL CHECKPOINT INHIBITORS REPRESENTS THE EMERGING SECTOR OF CANCER THERAPY, WITH AN EXPONENTIAL GROWTH MARKET. IN PARTICULAR, MONOCLONAL ANTIBODIES (MABS) CAPABLE OF INHIBITING CTLA-4, PD-1 AND PD-L1, APPROVED FOR SEVERAL SOLID TUMOURS AND HODGKIN’S LYMPHOMA, ARE ABLE TO REACTIVATE A GENERALISED ANTI-CANCER IMMUNE RESPONSE, PROVIDING FOR THE FIRST TIME A THERAPEUTIC AARMA TO PATIENTS WITH ADVANCED TUMOURS WITH REDUCED LIFE PERSPECTIVE. DESPITE LENTUSIASMO FOR THE RESULTS ACHIEVED SO FAR, MABS EFFICACY FOR IMMUNOTHERAPY APPROVED TO DATE IS LIMITED TO A PORTION OF TUMOURS (10-30 % OF CASES), AND IS FREQUENTLY ASSOCIATED WITH ALLÂINSORGERE OF AUTOIMMUNE ADVERSE EVENTS. THEREFORE, A LARGE PROPORTION OF TREATED PATIENTS (APPROXIMATELY 15 %) SHOULD DISCONTINUE DRUG TREATMENT DUE TO UNCURABLE ADVERSE REACTIONS. FINALLY, MANY PATIENTS ARE NOT ELIGIBLE FOR THESE TREATMENTS AT (English) / rank
 
Normal rank
Property / summary: LIMMUNOTERAPIA BASED ON IMMUNOLOGICAL CHECKPOINT INHIBITORS REPRESENTS THE EMERGING SECTOR OF CANCER THERAPY, WITH AN EXPONENTIAL GROWTH MARKET. IN PARTICULAR, MONOCLONAL ANTIBODIES (MABS) CAPABLE OF INHIBITING CTLA-4, PD-1 AND PD-L1, APPROVED FOR SEVERAL SOLID TUMOURS AND HODGKIN’S LYMPHOMA, ARE ABLE TO REACTIVATE A GENERALISED ANTI-CANCER IMMUNE RESPONSE, PROVIDING FOR THE FIRST TIME A THERAPEUTIC AARMA TO PATIENTS WITH ADVANCED TUMOURS WITH REDUCED LIFE PERSPECTIVE. DESPITE LENTUSIASMO FOR THE RESULTS ACHIEVED SO FAR, MABS EFFICACY FOR IMMUNOTHERAPY APPROVED TO DATE IS LIMITED TO A PORTION OF TUMOURS (10-30 % OF CASES), AND IS FREQUENTLY ASSOCIATED WITH ALLÂINSORGERE OF AUTOIMMUNE ADVERSE EVENTS. THEREFORE, A LARGE PROPORTION OF TREATED PATIENTS (APPROXIMATELY 15 %) SHOULD DISCONTINUE DRUG TREATMENT DUE TO UNCURABLE ADVERSE REACTIONS. FINALLY, MANY PATIENTS ARE NOT ELIGIBLE FOR THESE TREATMENTS AT (English) / qualifier
 
point in time: 31 January 2022
Timestamp+2022-01-31T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0

Revision as of 17:05, 31 January 2022

Project Q4191440 in Italy
Language Label Description Also known as
English
DEVELOPMENT OF NEW SECOND GENERATION MOLECULES FOR CANCER IMMUNOTHERAPY
Project Q4191440 in Italy

    Statements

    0 references
    2,083,794.25 Euro
    0 references
    4,167,588.5 Euro
    0 references
    50.0 percent
    0 references
    CHECKMAB S.R.L.
    0 references
    APHAD S.R.L.
    0 references
    ISTITUTI CLINICI SCIENTIFICI MAUGERI SOCIETA' PER AZIONI SOCIETA'BENEFIT IN FORMA ABBREVIATA "ISTITUTI CLINICI SCIENTIFICI MAUGERI SPA SB" O ANCHE "ICS MAUGERI SPA SB" O "MAUGERI SPA SB"
    0 references
    ITALFARMACO S.P.A.
    0 references
    ISTITUTO NAZIONALE TUMORI DI NAPOLI PASCALE
    0 references
    UNIVERSITà DEGLI STUDI DI MILANO - BICOCCA
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    L’IMMUNOTERAPIA BASATA SU INIBITORI DI CHECKPOINT IMMUNOLOGICI RAPPRESENTA IL SETTORE EMERGENTE DELLA TERAPIA ONCOLOGICA, CON UN MERCATO IN CRESCITA ESPONENZIALE. IN PARTICOLARE, GLI ANTICORPI MONOCLONALI (MABS) IN GRADO DI INIBIRE CTLA-4, PD-1 E PD-L1, APPROVATI PER DIVERSI TUMORI SOLIDI E PER IL LINFOMA DI HODGKIN, SONO IN GRADO DI RIATTIVARE UNA GENERALIZZATA RISPOSTA IMMUNITARIA ANTITUMORALE, FORNENDO PER LA PRIMA VOLTA UN’ARMA TERAPEUTICA A PAZIENTI AFFETTI DA TUMORI AVANZATI CON RIDOTTA PROSPETTIVA DI VITA. NONOSTANTE L’ENTUSIASMO PER I RISULTATI FIN QUI CONSEGUITI, L’EFFICACIA DEI MABS PER IMMUNOTERAPIA AD OGGI APPROVATI Ê LIMITATA AD UNA PORZIONE DI TUMORI (10-30% DEI CASI), ED Ê FREQUENTEMENTE ASSOCIATA ALL’INSORGERE DI EVENTI AVVERSI DI TIPO AUTOIMMUNE. PERTANTO, UNA COSPICUA PARTE DEI PAZIENTI TRATTATI (CIRCA 15%) DEVE INTERROMPERE IL TRATTAMENTO FARMACOLOGICO A CAUSA DI REAZIONI AVVERSE NON CURABILI. INFINE, MOLTI PAZIENTI NON SONO ELEGGIBILI A QUESTI TRATTAMENTI A (Italian)
    0 references
    LIMMUNOTERAPIA BASADO EN INHIBIDORES DE PUNTOS DE CONTROL INMUNOLÓGICOS REPRESENTA EL SECTOR EMERGENTE DE LA TERAPIA CONTRA EL CÁNCER, CON UN MERCADO DE CRECIMIENTO EXPONENCIAL. EN PARTICULAR, LOS ANTICUERPOS MONOCLONALES (MABS) CAPACES DE INHIBIR CTLA-4, PD-1 Y PD-L1, APROBADOS PARA VARIOS TUMORES SÓLIDOS Y LINFOMA HODGKIN’S, SON CAPACES DE REACTIVAR UNA RESPUESTA INMUNITARIA ANTICANCEROSA GENERALIZADA, PROPORCIONANDO POR PRIMERA VEZ UN AARMA TERAPÉUTICO A PACIENTES CON TUMORES AVANZADOS CON PERSPECTIVA DE VIDA REDUCIDA. A PESAR DE LENTUSIASMO PARA LOS RESULTADOS ALCANZADOS HASTA LA FECHA, LA EFICACIA DE MABS PARA INMUNOTERAPIA APROBADA HASTA LA FECHA SE LIMITA A UNA PORCIÓN DE TUMORES (10-30 % DE LOS CASOS), Y SE ASOCIA CON FRECUENCIA CON ALLINSORGERE DE EVENTOS ADVERSOS AUTOINMUNES. POR LO TANTO, UNA GRAN PROPORCIÓN DE PACIENTES TRATADOS (APROXIMADAMENTE 15 %) DEBE INTERRUMPIR EL TRATAMIENTO CON MEDICAMENTOS DEBIDO A REACCIONES ADVERSAS NO CURABLES. POR ÚLTIMO, MUCHOS PACIENTES NO SON ELEGIBLES PARA ESTOS TRATAMIENTOS EN (Spanish)
    31 January 2022
    0 references
    LIMMUNOTERAPIA BASED ON IMMUNOLOGICAL CHECKPOINT INHIBITORS REPRESENTS THE EMERGING SECTOR OF CANCER THERAPY, WITH AN EXPONENTIAL GROWTH MARKET. IN PARTICULAR, MONOCLONAL ANTIBODIES (MABS) CAPABLE OF INHIBITING CTLA-4, PD-1 AND PD-L1, APPROVED FOR SEVERAL SOLID TUMOURS AND HODGKIN’S LYMPHOMA, ARE ABLE TO REACTIVATE A GENERALISED ANTI-CANCER IMMUNE RESPONSE, PROVIDING FOR THE FIRST TIME A THERAPEUTIC AARMA TO PATIENTS WITH ADVANCED TUMOURS WITH REDUCED LIFE PERSPECTIVE. DESPITE LENTUSIASMO FOR THE RESULTS ACHIEVED SO FAR, MABS EFFICACY FOR IMMUNOTHERAPY APPROVED TO DATE IS LIMITED TO A PORTION OF TUMOURS (10-30 % OF CASES), AND IS FREQUENTLY ASSOCIATED WITH ALLÂINSORGERE OF AUTOIMMUNE ADVERSE EVENTS. THEREFORE, A LARGE PROPORTION OF TREATED PATIENTS (APPROXIMATELY 15 %) SHOULD DISCONTINUE DRUG TREATMENT DUE TO UNCURABLE ADVERSE REACTIONS. FINALLY, MANY PATIENTS ARE NOT ELIGIBLE FOR THESE TREATMENTS AT (English)
    31 January 2022
    0 references
    BUCCINASCO
    0 references
    CINISELLO BALSAMO
    0 references
    MILANO
    0 references
    PAVIA
    0 references
    MONZA
    0 references

    Identifiers